ArticleInvestigative ophthalmology & visual science2025
Antagonizing Viral MicroRNAs Reduces Ocular HSV-1 Pathogenesis and Enhances Mucosal Immune Homeostasis.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Evaluation and comparison of the clinical significance of miR-21-5p levels from different specimen sources in patients with fungal keratitis.BMC ophthalmology · 2026Article
- Viral microRNA inhibition enhances antiviral immunity by modulating corneal inflammatory and resolution pathways in HSV-1 induced keratitis.Experimental eye research · 2026Article
- IL-2: a promising topical treatment for Sjögren's disease-related dry eye disease.Arthritis research & therapy · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Purpose: Herpes simplex virus 1 (HSV-1) is a globally prevalent pathogen that causes recurrent lesions at mucosal and cutaneous sites, including the cornea, leading to herpetic keratitis, a major cause of infectious blindness. While HSV-1-encoded microRNAs (v-miRs) are known to regulate viral latency and immune evasion, their role in acute mucosal infection remains unclear. This study investigates the function of v-miRs during acute HSV-1 infection of the cornea. Methods: Using a murine model of corneal HSV-1 infection, we performed RNA sequencing and in situ hybridization to identify v-miRs enriched in the cornea during acute infection. Topical locked nucleic acid (LNA)-modified inhibitors targeting individual v-miRs (miR-H1-5p, miR-H3-3p, miR-H6-3p, and miR-H27) were administered, and effects on disease severity, viral replication, immune response, and lymphoid cell activation were assessed. Results: Inhibition of select v-miRs significantly attenuated corneal keratitis, reduced viral titers, and suppressed Th1/Th17-mediated inflammation. v-miR inhibition also decreased immune cell infiltration in draining lymph nodes and enhanced the frequency of IL-10-producing CD4⁺ T cells. Expression of immunoregulatory genes, including Arg1 and CD25, was increased, and T-cell proliferation was reduced ex vivo, indicating the establishment of a tissue-protective immune environment. Conclusions: HSV-1 v-miRs act as key immunoregulatory effectors during acute corneal infection. Their targeted inhibition using LNA-based therapy mitigates inflammation and promotes immune regulation, highlighting a novel therapeutic strategy for ocular HSV-1 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.